Clinical Omics – Products

Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development.

New, easy-to-use analytical detection system extracts meaningful data quickly from acquisition to analysis.

At the 66th ASMS Conference, Bruker announces innovative mass spectrometry products and workflows for breakthroughs in life-science research, in clinical research and large-cohort validations in phenomics and proteomics, in novel biopharma applications and in applied toxicology and forensics markets.

Creating access to the power and potential of mass spectrometry for more laboratories.

Daiichi Sankyo and Takeda Pharmaceuticals to leverage FDA-approved test for clinical trials and drug development programs.

New pan-cancer cell-free total nucleic acid (cfTNA) assay and FFPE-based tumor mutation load analysis assay, coupled with new Ion AmpliSeq HD technology, extend industry-leading Oncomine menu and enable panel design customization.

Thermo Fisher Scientific today announced the Ion GeneStudio S5 Series, a new line of bench top next-generation sequencing (NGS) instruments that enable low cost per sample for small and large projects across multiple research applications.

The FDA-approved next-generation sequencing (NGS) kit will help clinicians identify which patients are eligible for treatment of metastatic colorectal cancer.

The Thermo Scientific Cascadion SM Clinical Analyzer brings together the ease of use of clinical analyzers with the selectivity and sensitivity of liquid chromatography-tandem mass spectrometry (LC-MS/MS).

Bruker’s novel Proteoform Profiling™ 1.0 solution enables a powerful new life-science research and translational research workflow.